June 08, 2020
The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.
June 03, 2020
The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.
May 30, 2020
A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results.
Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.
May 29, 2020
The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.
An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.
“Data collection is ongoing with additional analyses planned to look at patient and provider perception of COVID-19 impact on cancer care.”
SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.
The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.
May 28, 2020
The findings, which were presented virtually in the 2020 ASCO Virtual Scientific Program, included the association between treatment with hydroxychloroquine plus azithromycin and increased risk of death.
